Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Rapid Funding for DSEN Targeted Research

University of British Columbia

$100,088.00

Factors Contributing to the Development of Preventable Adverse Drug Events

FY 2016-17

Summary
This study aims to describe preventable adverse drug events and to investigate potentially modifiable factors associated with these events. To do this, a study pharmacist will access medical charts for a cohort of adverse drug event patients that presented to the emergency departments of five Canadian hospitals between 2008 and 2015. The pharmacist will review the charts to investigate the preventability of each adverse drug event. The pharmacist will categorize these events by reaction type, severity and drug class, and attribute these events to factors at the system, patient and provider-level. In addition to investigating the overall preventability of adverse drug events, the investigators will also look specifically at the rate of unintentional re-exposure to previously harmful medications. The investigators will determine the patient, provider, and system-level risk factors related to these re-exposures. By identifying potentially modifiable factors associated with adverse drug events, we intend to provide guidance in the development of effective, evidence-based strategies for adverse drug event prevention.
Program
Rapid Funding for DSEN Targeted Research
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
350880
Name
Hohl Corinne M
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases
Projecttitle
Factors Contributing to the Development of Preventable Adverse Drug Events
Programtype2
Miscellaneous Programs
Orgnameinp2
University of British Columbia
Cihramount2
$100,088
Cihrequipment2
$0
Programname2
Rapid Funding for DSEN Targeted Research
Keyworddelim
Adverse Drug Event; Dsen
Abstract
This study aims to describe preventable adverse drug events and to investigate potentially modifiable factors associated with these events. To do this, a study pharmacist will access medical charts for a cohort of adverse drug event patients that presented to the emergency departments of five Canadian hospitals between 2008 and 2015. The pharmacist will review the charts to investigate the preventability of each adverse drug event. The pharmacist will categorize these events by reaction type, severity and drug class, and attribute these events to factors at the system, patient and provider-level. In addition to investigating the overall preventability of adverse drug events, the investigators will also look specifically at the rate of unintentional re-exposure to previously harmful medications. The investigators will determine the patient, provider, and system-level risk factors related to these re-exposures. By identifying potentially modifiable factors associated with adverse drug events, we intend to provide guidance in the development of effective, evidence-based strategies for adverse drug event prevention.
Competitiondate
201606
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hohl, Corinne M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,088~ $0~